Advancing excellence in laboratory medicine for better healthcare worldwide

Value Proposition for Laboratory Medicine (C-VPLM)

Membership

Name

Position

Country

Term

Time in Office

A. St John

Chair

AU

1st

2018 01 - 2020 12

R. Christenson

Member

US1st

2018 03 - 2020 12

M.O'Kane

Member

UK1st

2018 03 - 2020 12

P.Jüelicher

Member

DE1st

2018 03 - 2020 12

F.CurcioWASPaLM Rep.

IT

M.Oellerich WASPaLM Rep.

DE

I.Parwati WASPaLM Rep.

ID

N.Massakazu Sumita WASPaLM Rep.

BR

R.Verna WASPaLM Rep.

IT

C. Price Consultant

UK

Terms of reference

1. To advocate adoption of the value proposition in laboratory medicine/healthcare

Continuing work in the form of peer-reviewed publications, congress symposia and presentations to local meetings is required to describe and define the value proposition in laboratory medicine and to advocate its widespread adoption. During the first 3 years of this committee it is intended that this work would be restricted to laboratory medicine professionals albeit with interaction with appropriate clinical specialists relevant to the particular tests As the group expands the body of knowledge on the value proposition in firstly laboratory medicine and then in other healthcare disciplines then this work can be extended.

2. To develop a compendium of tools for laboratory medicine specialists to establish the value for individual medical tests within individual    health care systems.

Case studies will be undertaken for specific medical tests according to the principles of the value proposition in specific healthcare systems. There is a need to develop the principles for the preparation of such case studies for publication in the current peer-reviewed journals in order that they reach the appropriate audience. This work has been commenced and will continue for 3 years. It will include test laboratories applying the value proposition framework to a particular medical test and assessing the outcomes. At the end of this period it is proposed that a compendium of tools generalisable for the preparation of documents demonstrating the value proposition for any medical test will be described in a major review publication.

List of Corresponding Members, nominated by National Societies:

Name

National Society

Country

F.B. Aksungar

Turkish Biochemical SocietyTR
T. BadrickAustralasian Association of Clinical BiochemistsAU
M. Barrionuevo GonzalezSociedad Española de Medicina de LaboratorioES
P. LaitinenFinnish Society of Clinical ChemistryFI
K. SaitoJapan Society of Clinical ChemistryJP
D.GrenacheAmerican Association Clinical ChemistryUS

List of Corresponding Members, nominated by Corporate Members:

Name

Company

 

B.Milojkovic

NOVA BIOMEDICAL

Committee Chair's contact:

Dr. Andrew St.John
ARC Consulting
14 Learoyd Street
MT Lawley, WA, 6050
Australia
email: astjohn14@gmail.com

 
Website developed by Insoft